To view this email as a web page, click here.
 
PHARMACISTS' REPORT
 
Removing DIR Fees Could Save Billions
A study commissioned by the NCPA shows the effect of DIR fees.
Read more
 
ADVERTISEMENT
 
Drug Topics Pharmacist Health Care Survey
Health-care reform will always be an issue, but what do pharmacists want?
Read more
 
Rivaroxaban Shown to Cut Risk of Cardiovascular Events
The latest studies on Rivaroxaban (Xarelto, Janssen/Bayer) are in.
Read more
 
The Worst Pharmacy Bosses of All Time
Sometimes the people on top make your life miserable.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.